Alteplase has 6 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Defibrotide Sodium, Antiplatelet Drugs, Nitroglycerin. Patients taking Alteplase should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 6
- Contraindicated
- 1
- Major
- 4
- Moderate
- 1
Contraindicated (1)
- Alteplase + Defibrotide Sodium— DEFITELIO may enhance the pharmacodynamic activity of alteplase, increasing risk of hemorrhage. Concomitant use is contr…
Major (4)
- Alteplase + Antiplatelet Drugs— Antiplatelet drugs increase the risk of bleeding if administered prior to, during, or after Alteplase therapy.
- Alteplase + Nitroglycerin— Intravenous nitroglycerin decreases the thrombolytic effect of alteplase; caution advised with sublingual nitroglycerin …
- Alteplase + Oral Anticoagulants— Anticoagulants increase the risk of bleeding if administered prior to, during, or after Alteplase therapy.
- Alteplase + Tranexamic Acid— Concomitant therapy may decrease the efficacy of both tranexamic acid and tissue plasminogen activators. Discontinue tra…
Moderate (1)
- Alteplase + Angiotensin Ii— Concomitant angiotensin-converting enzyme inhibitors may increase the risk of angioedema, particularly in patients with …